Commonwealth of Pennsylvania Public School Empls Retrmt SYS Has $22.32 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Commonwealth of Pennsylvania Public School Empls Retrmt SYS decreased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.1% in the first quarter, according to its most recent 13F filing with the SEC. The firm owned 23,192 shares of the biopharmaceutical company’s stock after selling 268 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in Regeneron Pharmaceuticals were worth $22,322,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of the business. US Bancorp DE increased its stake in shares of Regeneron Pharmaceuticals by 1.4% during the 1st quarter. US Bancorp DE now owns 5,010 shares of the biopharmaceutical company’s stock worth $4,822,000 after purchasing an additional 69 shares during the last quarter. Russell Investments Group Ltd. grew its stake in Regeneron Pharmaceuticals by 6.2% in the 1st quarter. Russell Investments Group Ltd. now owns 128,511 shares of the biopharmaceutical company’s stock valued at $123,710,000 after buying an additional 7,481 shares during the last quarter. QRG Capital Management Inc. raised its holdings in Regeneron Pharmaceuticals by 4.8% in the 1st quarter. QRG Capital Management Inc. now owns 21,502 shares of the biopharmaceutical company’s stock worth $20,695,000 after acquiring an additional 985 shares during the period. Williams Jones Wealth Management LLC. raised its holdings in Regeneron Pharmaceuticals by 3.4% in the 1st quarter. Williams Jones Wealth Management LLC. now owns 1,779 shares of the biopharmaceutical company’s stock worth $1,712,000 after acquiring an additional 58 shares during the period. Finally, Delta Financial Advisors LLC boosted its holdings in Regeneron Pharmaceuticals by 1.1% during the first quarter. Delta Financial Advisors LLC now owns 1,395 shares of the biopharmaceutical company’s stock valued at $1,343,000 after acquiring an additional 15 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

REGN stock traded down $10.46 during mid-day trading on Wednesday, hitting $1,084.53. 257,513 shares of the company were exchanged, compared to its average volume of 469,715. Regeneron Pharmaceuticals, Inc. has a 1-year low of $715.54 and a 1-year high of $1,106.16. The stock has a market capitalization of $119.50 billion, a PE ratio of 32.35, a price-to-earnings-growth ratio of 2.24 and a beta of 0.13. The business has a 50 day simple moving average of $1,018.69 and a 200-day simple moving average of $968.60. The company has a current ratio of 5.27, a quick ratio of 4.51 and a debt-to-equity ratio of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $8.46 by ($0.49). The company had revenue of $3.15 billion for the quarter, compared to analyst estimates of $3.19 billion. Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. On average, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.17 earnings per share for the current year.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Michael S. Brown sold 1,172 shares of the firm’s stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $974.86, for a total value of $1,142,535.92. Following the sale, the director now owns 1,382 shares in the company, valued at $1,347,256.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, Director Michael S. Brown sold 1,172 shares of the stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $974.86, for a total value of $1,142,535.92. Following the completion of the sale, the director now directly owns 1,382 shares in the company, valued at $1,347,256.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Leonard S. Schleifer sold 22,830 shares of the firm’s stock in a transaction dated Friday, May 17th. The stock was sold at an average price of $979.23, for a total value of $22,355,820.90. Following the transaction, the chief executive officer now owns 466,877 shares of the company’s stock, valued at $457,179,964.71. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 65,074 shares of company stock valued at $64,546,123. 7.48% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several equities analysts recently weighed in on REGN shares. Royal Bank of Canada reissued an “outperform” rating and set a $1,229.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Monday, June 24th. Evercore ISI assumed coverage on Regeneron Pharmaceuticals in a report on Tuesday, May 14th. They issued an “outperform” rating and a $1,150.00 target price for the company. Truist Financial reiterated a “buy” rating and set a $1,135.00 target price on shares of Regeneron Pharmaceuticals in a research report on Wednesday, April 3rd. UBS Group lifted their price target on shares of Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the company a “buy” rating in a report on Wednesday, April 17th. Finally, Cantor Fitzgerald reissued a “neutral” rating and issued a $925.00 price target on shares of Regeneron Pharmaceuticals in a report on Friday, May 3rd. One analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $1,038.77.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.